Cynata Therapeutics (CYP) Q2 2025 TU earnings summary

Executive summary

• Completed a successful financing round, maintaining key shareholders and increasing market cap to over AUD 55 million.

• Completed Phase 1 DFU trial with CYP-006TK, demonstrating safety, tolerability, and significant efficacy, with an 83.6% wound area reduction at 24 weeks versus 47.8% for standard care.

• Four active clinical programs: acute graft-versus-host disease (GVHD/aGvHD), diabetic foot ulcers (DFU), osteoarthritis, and kidney transplantation, with two internally funded and two partner-funded.

• Significant clinical milestones achieved: positive phase I DFU results, progress in phase II GVHD (over 40% enrolled, results late 2025), first patient treated in kidney transplant trial (cohort 1 results expected H1 2025), and completion of final patient treatment in phase III osteoarthritis (results 1H 2026).

• Strengthened balance sheet with $10.51m cash at quarter end, supported by $8.10m institutional placement and $1.88m R&D tax incentive rebate, providing runway into mid-2026.

Financial highlights

• Raised $8.10m via institutional placement and received $1.88m R&D tax incentive rebate.

• Ended the quarter with $10.51m in cash and cash equivalents, with net operating cash outflows of $1.26m.

• Market capitalisation over AUD 55 million; share price at A$0.245 as of 5 February 2025.

• Top 20 shareholders hold about 47% of shares on issue.

• Estimated 8.3 quarters of funding available based on current cash and outflows.

Outlook and guidance

• Anticipates completion of GVHD/aGvHD phase II enrollment in 1H 2025, with results expected late 2025.

• Osteoarthritis phase III follow-up to conclude in November 2025, with results in 1H 2026.

• Initial results from the kidney transplant trial's first cohort expected in H1 2025.

• Results from three additional clinical trials expected by 1H 2026, including aGvHD, osteoarthritis, and kidney transplant.

• Ongoing engagement with potential partners and regulators for DFU program advancement and partnering discussions expected to accelerate.